Innate Pharma S.A. (EPA:IPH)
France
· Delayed Price · Currency is EUR 1.752
-0.052 (-2.88%)
Apr 24, 2025, 3:37 PM CET
Innate Pharma Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -49.47 | -7.57 | -58.1 | -52.81 | -63.98 | Upgrade
|
| Depreciation & Amortization | 1.99 | 5.09 | 4.41 | 4.6 | 13.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.02 | -0.52 | - | -0.37 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 41 | - | 43.53 | Upgrade
|
| Loss (Gain) From Sale of Investments | -2.6 | -1.59 | 1.37 | -0.99 | 0.58 | Upgrade
|
| Stock-Based Compensation | 3.94 | 4.26 | 4.25 | 2.62 | 2.48 | Upgrade
|
| Other Operating Activities | 0.06 | -0.13 | 0.43 | -1.62 | 1.57 | Upgrade
|
| Change in Accounts Receivable | - | -13.67 | -4.2 | - | -22.92 | Upgrade
|
| Change in Accounts Payable | - | -3.89 | -7.66 | - | -6.53 | Upgrade
|
| Change in Unearned Revenue | - | -4 | -23.43 | - | -45.14 | Upgrade
|
| Change in Other Net Operating Assets | 39.16 | -10.53 | 22.8 | -9.89 | 25.38 | Upgrade
|
| Operating Cash Flow | -6.9 | -32.56 | -19.16 | -58.46 | -51.77 | Upgrade
|
| Capital Expenditures | -0.39 | -0.35 | -0.54 | -0.93 | -0.91 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.15 | - | 0.01 | 0.01 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -2 | -0.59 | -0.4 | -10.38 | Upgrade
|
| Investment in Securities | 9.59 | 22.77 | 3 | - | -3 | Upgrade
|
| Other Investing Activities | 0 | 0.06 | -0 | 0.41 | 0.9 | Upgrade
|
| Investing Cash Flow | 9.2 | 20.63 | 1.88 | -0.92 | -13.37 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 28.7 | 1.36 | Upgrade
|
| Long-Term Debt Repaid | -8.94 | -2.36 | -2.03 | -2.07 | -2.25 | Upgrade
|
| Net Debt Issued (Repaid) | -8.94 | -2.36 | -2.03 | 26.63 | -0.89 | Upgrade
|
| Issuance of Common Stock | 2.93 | 0.4 | 0.2 | 0.5 | 0.05 | Upgrade
|
| Other Financing Activities | - | - | - | -0.31 | -0.34 | Upgrade
|
| Financing Cash Flow | -6.01 | -1.97 | -1.83 | 26.82 | -1.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.51 | 0.27 | -0.43 | -0.48 | 0.22 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | 0 | -0 | -0 | Upgrade
|
| Net Cash Flow | -4.21 | -13.62 | -19.53 | -33.04 | -66.1 | Upgrade
|
| Free Cash Flow | -7.29 | -32.91 | -19.69 | -59.39 | -52.67 | Upgrade
|
| Free Cash Flow Margin | -36.22% | -53.39% | -34.14% | -240.40% | -75.49% | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.41 | -0.25 | -0.75 | -0.67 | Upgrade
|
| Cash Interest Paid | - | - | - | 0.31 | 0.34 | Upgrade
|
| Levered Free Cash Flow | 16.11 | -27.07 | -32.74 | -15.02 | -74.5 | Upgrade
|
| Unlevered Free Cash Flow | 17.47 | -26.67 | -32.56 | -14.82 | -74.28 | Upgrade
|
| Change in Net Working Capital | -44.16 | 25.75 | 29.83 | -9.19 | 79.42 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.